Spain's Grifols SA (GRF.MC) said Monday it has reached an agreement to buy U.S.-maker of plasma medicines Talecris Biotherapeutics Holdings Corp. (TLCR) for $3.4 billion in cash and shares.

The Wall Street Journal reported late Sunday the two companies were close to a deal.

In a Spanish regulatory filing, Grifols said it will derive synergies of around $230 million from the purchase. One of the world's largest maker of plasma products, Grifols already has operations in the U.S.

-By Jonathan House, Dow Jones Newswires; +34 91 395 8120; jonathan.house@dowjones.com
Grifols (PK) (USOTC:GIKLY)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024 Haga Click aquí para más Gráficas Grifols (PK).
Grifols (PK) (USOTC:GIKLY)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024 Haga Click aquí para más Gráficas Grifols (PK).